

11

Absorption and Distribution of Glucosamine and Chondroitin

This study is currently recruiting patients.

Sponsored by

National Center for Complementary and Alternative Medicine (NCCAM)

Purpose

The purpose of this study is to examine the way the dietary supplements glucosamine and chondroitin are absorbed and distributed throughout the body.

Condition	Treatment or Intervention
Osteoarthritis	Drug: Glucosamine Drug: Chondroitin

MedlinePlus related topics: Osteoarthritis

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Pharmacokinetics Study

Official Title: A Pharmacokinetic Study of Glucosamine and Chondroitin

Further Study Details:

Expected Total Enrollment: 70

Study start: April 2004

Osteoarthritis is the most common musculoskeletal disease in the world. While predisposing conditions have been identified, the actual cause of osteoarthritis remains unknown. Traditional treatments, most often anti-inflammatory drugs and pain relievers, produce variable results and may cause significant toxicity. The use of complementary and alternative therapies in the treatment of osteoarthritis has become more common, and particular interest has focused on glucosamine and chondroitin treatments. This study will examine the pharmacokinetics of glucosamine and chondroitin.

This study consists of two phases. In Phase I, participants will have two study visits, during which multiple blood samples will be taken in order to determine levels of glucosamine and chondroitin found naturally in the body. During Phase II, participants will be randomly assigned to receive glucosamine, chondroitin, or a combination of the two for 3 months. Blood samples will be taken at each of the three Phase II study visits to examine the

pharmacokinetics of glucosamine and chondroitin.

Eligibility

Ages Eligible for Study: 21 Years and above, Genders Eligible for Study: Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

- Able to walk

Exclusion Criteria:

- Allergy to glucosamine, chondroitin, or shellfish
- Liver or kidney disease
- Diabetes mellitus
- Concurrent use of other complementary or alternative therapies

Location and Contact Information

Utah

University of Utah Health Sciences Center, Salt Lake City, Utah, 84132, United States; Recruiting

Kalli Cooper 801-581-7724

Christopher G. Jackson, MD, Principal Investigator

More Information

Study ID Numbers: 1-R21-AT001938-01

Record last reviewed: June 2004

Record first received: June 28, 2004

ClinicalTrials.gov Identifier: NCT00086229

ClinicalTrials.gov processed this record on 2004-09-07

[U.S. National Library of Medicine, Contact NLM Customer Service](#)
[National Institutes of Health, Department of Health & Human Services](#)
[Copyright, Privacy, Accessibility, Freedom of Information Act](#)